title: Feasibility study of docetaxel and nedaplatin for recurrent squamous cell carcinoma of the uterine cervix.
abstract: BACKGROUND
  To determine a new taxane plus platinum treatment regimen for squamous cell carcinoma of the uterine cervix (CSCC), a phase I feasibility study of docetaxel (DTX) plus nedaplatin (CDGP) combination therapy was conducted.
  
  
  METHODS
  Twenty consecutive patients were enrolled into the study. The starting dose of DTX/CDGP was 60 mg/m2 / 80 mg/m2, every 4 weeks for at least three courses and the dose was escalated to 70 mg/m2 / 100 mg/m2. DTX 60 mg/m2 / CDGP 100 mg/m2 was also evaluated as an extra dose level.
  
  
  RESULTS
  Dose-limiting toxicity was granulocytopenia and the maximum tolerated dose was determined as 70 mg/m2 / 100 mg/m2. All 20 patients had measurable disease and a partial response was achieved in 8 (40.0%) patients.
  
  
  CONCLUSIONS
  DTX/CDGP therapy appears to be a tolerable regimen for cervical squamous cell carcinoma, even in patients previously treated by cisplatin concurrent chemoradiotherapy. The recommended doses of DTX and CDGP were determined to be 60 mg/m2 and 100 mg/m2, respectively.
authors.affiliation: Department of Obstetrics and Gynecology, Kinki University School of Medicine, 377-2 Ohno-Higashi Osakasayama Osaka 589-8511, Japan. watanabe@med.kindai.ac.jp
authors.forename: Yoh
authors.initials: Y
authors.lastname: Watanabe
authors.forename: Hidekatsu
authors.initials: H
authors.lastname: Nakai
authors.forename: Tomomaro
authors.initials: T
authors.lastname: Etoh
authors.forename: Kazumi
authors.initials: K
authors.lastname: Kanemura
authors.forename: Isao
authors.initials: I
authors.lastname: Tsuji
authors.forename: Ayako
authors.initials: A
authors.lastname: Ishizu
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Hoshiai